GSK PLC SP. ADR/2 NEW Asset Resilience Ratio
GSK PLC SP. ADR/2 NEW asset resilience ratio. GSK PLC SP. ADR/2 NEW (GS70) has an Asset Resilience Ratio of 0.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of GSK PLC SP. ADR/2 NEW to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of GSK PLC SP. ADR/2 NEW (2021–2025)
Asset resilience ratio of GSK PLC SP. ADR/2 NEW from 2021 to 2025. This chart shows how GSK PLC SP. ADR/2 NEW's Asset Resilience Ratio has changed over time. Read GS70 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down GSK PLC SP. ADR/2 NEW's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see GS70 total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.00 Million | 0.0% |
| Total Liquid Assets | €1.00 Million | 0.00% |
Asset Resilience Insights
- Limited Liquidity: GSK PLC SP. ADR/2 NEW maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
GSK PLC SP. ADR/2 NEW Industry Peers by Asset Resilience Ratio
Compare GSK PLC SP. ADR/2 NEW's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
GSK PLC SP. ADR/2 NEW Asset Resilience Ratio by Year (2021–2025)
GSK PLC SP. ADR/2 NEW asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for GSK PLC SP. ADR/2 NEW.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.01% | €9.00 Million ≈ $10.52 Million |
€61.12 Billion ≈ $71.45 Billion |
-0.02pp |
| 2024-12-31 | 0.04% | €21.00 Million ≈ $24.55 Million |
€59.46 Billion ≈ $69.52 Billion |
-3.77pp |
| 2023-12-31 | 3.81% | €2.25 Billion ≈ $2.63 Billion |
€59.01 Billion ≈ $68.98 Billion |
-3.10pp |
| 2022-12-31 | 6.91% | €4.15 Billion ≈ $4.86 Billion |
€60.15 Billion ≈ $70.32 Billion |
+6.83pp |
| 2021-12-31 | 0.08% | €61.00 Million ≈ $71.32 Million |
€79.10 Billion ≈ $92.48 Billion |
-- |
About GSK PLC SP. ADR/2 NEW
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more